Daiichi Sankyo’s Ezharmia Receives Japanese Approval For T-Cell Lymphoma
25 Jun 2024 //
PHARMABIZ
Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy
20 Dec 2022 //
INDIANPHARMAPOST
Valemetostat NDA Submitted in Japan for Adult T-Cell Leukemia/Lymphoma
28 Dec 2021 //
BUSINESSWIRE
Valemetostat Pivotal Data Shows Promising Response Rates in ATL
11 Dec 2021 //
BUSINESSWIRE
Valemetostat Data at EHA Shows Promising Durable Tumor Response
11 Jun 2021 //
BUSINESSWIRE
Valemetostat Data at EHA Shows Promising Durable Tumor Response
11 Jun 2021 //
BUSINESSWIRE